Starling Oncology, Inc. Common Stock STLN

$6.73 +1.05% at last close

Recent SEC Filings

FormDescriptionFiledDocument
8-K FORM 8-K 2026-09-02 View →
4 Insider transaction 2026-08-24 View →
8-K FORM 8-K 2026-08-21 View →
4 OWNERSHIP DOCUMENT 2026-08-17 View →
10-Q 10-Q 2026-08-06 View →
8-K FORM 8-K 2026-08-06 View →
8-K FORM 8-K 2026-08-03 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 Insider transaction 2026-07-29 View →
4 OWNERSHIP DOCUMENT 2026-07-22 View →
4 Insider transaction 2026-07-16 View →
4 OWNERSHIP DOCUMENT 2026-07-13 View →
4 Insider transaction 2026-07-09 View →
4 Insider transaction 2026-07-09 View →
8-K FORM 8-K 2026-07-07 View →
4 OWNERSHIP DOCUMENT 2026-06-24 View →
8-K FORM 8-K 2026-06-18 View →
4 Insider transaction 2026-06-09 View →
4 OWNERSHIP DOCUMENT 2026-06-05 View →
4 Insider transaction 2026-05-22 View →
4 Insider transaction 2026-05-22 View →
4 Insider transaction 2026-05-22 View →
8-K FORM 8-K 2026-05-22 View →
4 OWNERSHIP DOCUMENT 2026-05-21 View →
4 OWNERSHIP DOCUMENT 2026-05-20 View →
8-K FORM 8-K 2026-05-07 View →
10-Q 10-Q 2026-05-07 View →
DEF 14A DEF 14A 2026-04-30 View →
4 Insider transaction 2026-04-23 View →
4 Insider transaction 2026-04-23 View →
4 Insider transaction 2026-04-16 View →
4 OWNERSHIP DOCUMENT 2026-04-13 View →
4 Insider transaction 2026-04-01 View →
4 Insider transaction 2026-04-01 View →
4 Insider transaction 2026-04-01 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$6.73
Market Cap
$678.76 million
52-Week Range
$4.85 – $7.13
Average Volume
1.27 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.